{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:32:29Z","timestamp":1787315549031,"version":"build-2736575974"},"reference-count":105,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Circ"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/bc.bc_42_19","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T10:08:14Z","timestamp":1593166094000},"page":"70","source":"Crossref","is-referenced-by-count":57,"title":["Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review"],"prefix":"10.4103","volume":"6","author":[{"given":"HayderM","family":"Al-Kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MayH","family":"Abdulhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NawarR","family":"Hussien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MarwaS","family":"Al-Niemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HudaA","family":"Rasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AliI","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2394-8108.287734-1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuropharm.2018.10.024","article-title":"Reactive and predictive homeostasis: Roles of orexin\/hypocretin neurons","author":"Burdakov","year":"2019","journal-title":"Neuropharmacology"},{"key":"key-10.4103\/2394-8108.287734-2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18097\/PBMC20186405451","article-title":"Chronic alcoholism influences the mRNA level of the orexin receptor type 1 (OX1R) in emotiogenic structures of the rat brain","author":"Airapetov","year":"2018","journal-title":"Biomed Khim"},{"key":"key-10.4103\/2394-8108.287734-3","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/adb.12672","article-title":"Orexin-mediated restoration of hippocampal synaptic potentiation in mice with established cocaine-conditioned place preference","author":"Lu","year":"2019","journal-title":"Addict Biol"},{"key":"key-10.4103\/2394-8108.287734-4","doi-asserted-by":"crossref","first-page":"E9489","DOI":"10.1073\/pnas.1802237115","article-title":"Uneven balance of power between hypothalamic peptidergic neurons in the control of feeding","author":"Wei","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.287734-5","doi-asserted-by":"crossref","first-page":"13669","DOI":"10.1074\/jbc.M115.646885","article-title":"Negative regulation of leptin-induced reactive oxygen species (ROS) formation by cannabinoid CB1 receptor activation in hypothalamic neurons","author":"Palomba","year":"2015","journal-title":"J Biol Chem"},{"key":"key-10.4103\/2394-8108.287734-6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.npep.2012.10.003","article-title":"Novel orexigenic pathway prostaglandin D2-NPY system-involvement in orally active orexigenic \u03b4 opioid peptide","author":"Kaneko","year":"2012","journal-title":"Neuropeptides"},{"key":"key-10.4103\/2394-8108.287734-7","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM, Al-Gareeb AI. Central beneficial effects of trimetazidine on psychomotor performance in normal healthy volunteers. Advanced Biomedical Res 2017;6.23-9.","DOI":"10.4103\/2277-9175.190994"},{"key":"key-10.4103\/2394-8108.287734-8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.peptides.2018.10.011","article-title":"Intra-hippocampal administration of orexin receptor antagonists dose-dependently attenuates reinstatement of morphine seeking behavior in extinguished rats","author":"Alizamini","year":"2018","journal-title":"Peptides"},{"key":"key-10.4103\/2394-8108.287734-9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/bc.bc_46_19","article-title":"Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circulation"},{"key":"key-10.4103\/2394-8108.287734-10","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1523\/JNEUROSCI.0719-05.2005","article-title":"Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: Correlation with improved attention in rat","author":"Lambe","year":"2005","journal-title":"J Neurosci"},{"key":"key-10.4103\/2394-8108.287734-11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.brainres.2014.10.041","article-title":"Orexin receptor activity in the basal forebrain alters performance on an olfactory discrimination task","author":"Piantadosi","year":"2015","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-12","first-page":"85","article-title":"Exercise influence on hippocampal function: possible involvement of orexin-A","author":"Chieffi","year":"2017","journal-title":"Front Physiol"},{"key":"key-10.4103\/2394-8108.287734-13","doi-asserted-by":"crossref","first-page":"145921","DOI":"10.1016\/j.brainres.2018.08.024","article-title":"Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction","author":"Calva","year":"2020","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13041-015-0106-1","article-title":"The role of orexin in post-stroke inflammation, cognitive decline, and depression","author":"Song","year":"2015","journal-title":"Mol Brain"},{"key":"key-10.4103\/2394-8108.287734-15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.bbrc.2010.10.115","article-title":"Angiogenic role of orexin-A via the activation of extracellular signal-regulated kinase in endothelial cells","author":"Kim","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.4103\/2394-8108.287734-16","first-page":"179ra44","article-title":"Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition","author":"Uslaner","year":"2013","journal-title":"Sci Transl Med"},{"key":"key-10.4103\/2394-8108.287734-17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopha.2018.10.033","article-title":"Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice","author":"Alijanpour","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"key-10.4103\/2394-8108.287734-18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygcen.2016.09.013","article-title":"Orexin receptor expression in the hypothalamic-pituitary-adrenal and hypothalamic- pituitary-gonadal axes of free-living European beavers (Castor fiber L.) in different periods of the reproductive cycle","author":"Czerwinska","year":"2017","journal-title":"Gen Comp Endocrinol"},{"key":"key-10.4103\/2394-8108.287734-19","first-page":"401","article-title":"Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland","author":"Malendowicz","year":"2001","journal-title":"Int J Mol Med"},{"key":"key-10.4103\/2394-8108.287734-20","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s00213-014-3520-7","article-title":"Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and alprazolam following insulin-induced hypoglycemia in humans","author":"Patel","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/2394-8108.287734-21","first-page":"112","article-title":"Prolactin and risk of preeclampsia: A single institution, cross-sectional study","author":"Al-Maiahy","year":"2019","journal-title":"Asian Pacific J Reproduction"},{"key":"key-10.4103\/2394-8108.287734-22","doi-asserted-by":"crossref","unstructured":"Samson WK, Bagley SL, Ferguson AV, White MM. Hypocretin\/orexin type 1 receptor in brain: Role in cardiovascular control and the neuroendocrine response to immobilization stress. Am J Physiol Regul Integr Comp Physiol 2007;292:R382-7.","DOI":"10.1152\/ajpregu.00496.2006"},{"key":"key-10.4103\/2394-8108.287734-23","first-page":"S88","article-title":"Berberine attenuates olanzapine induced-metabolic syndrome.JPMA","author":"Al-Naimi","year":"2019","journal-title":"The J Pakistan Medical Association"},{"key":"key-10.4103\/2394-8108.287734-24","first-page":"309","article-title":"Plasma ghrelin, leptin, and orexin-A levels and insulin resistance after laparoscopic gastric band applications in morbidly obese patients","author":"Cigdem","year":"2013","journal-title":"Minerva Med"},{"key":"key-10.4103\/2394-8108.287734-25","unstructured":"Mediavilla C, Risco S. Orexin: Clinical and therapeutic implications. Rev Neurol 2014;58:117-24."},{"key":"key-10.4103\/2394-8108.287734-26","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/en.2016-1404","article-title":"Timed inhibition of orexin system by suvorexant improved sleep and glucose metabolism in type 2 diabetic db\/db mice","author":"Tsuneki","year":"2016","journal-title":"Endocrinology"},{"key":"key-10.4103\/2394-8108.287734-27","first-page":"256","article-title":"Cannabinoid\u2013hypocretin cross-talk in the central nervous system: What we know so far","author":"Flores","year":"2013","journal-title":"Front Neurosci"},{"key":"key-10.4103\/2394-8108.287734-28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neubiorev.2017.03.007","article-title":"Serotonin and neuroplasticity-Links between molecular, functional and structural pathophysiology in depression","author":"Kraus","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"key-10.4103\/2394-8108.287734-29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/jcem.87.2.8246","article-title":"Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans","author":"Kok","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.4103\/2394-8108.287734-30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/sleep\/29.3.295","article-title":"Diurnal variation in CSF orexin-A in healthy male subjects","author":"Grady","year":"2006","journal-title":"Sleep"},{"key":"key-10.4103\/2394-8108.287734-31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2018.12.008","article-title":"Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review","author":"Shariq","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/0269881106082899","article-title":"Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine","author":"Feng","year":"2008","journal-title":"J Psychopharmacol"},{"key":"key-10.4103\/2394-8108.287734-33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/17470919.2016.1169216","article-title":"Relationship between orexin A and childhood maltreatment in female patients with depression and anxiety","author":"Ozsoy","year":"2017","journal-title":"Soc Neurosci"},{"key":"key-10.4103\/2394-8108.287734-34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.npep.2004.06.004","article-title":"Stereological analysis of the hypothalamic hypocretin\/orexin neurons in an animal model of depression","author":"Allard","year":"2004","journal-title":"Neuropeptides"},{"key":"key-10.4103\/2394-8108.287734-35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2006.10.019","article-title":"Orexin and psychiatric symptoms in suicide attempters","author":"Brundin","year":"2007","journal-title":"J Affect Disord"},{"key":"key-10.4103\/2394-8108.287734-36","doi-asserted-by":"crossref","unstructured":"Ito N, Yabe T, Gamo Y, Nagai T, Oikawa T, Yamada H, et al. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 2008;157:720-32.","DOI":"10.1016\/j.neuroscience.2008.09.042"},{"key":"key-10.4103\/2394-8108.287734-37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41380-018-0127-0","article-title":"Orexin prevents depressive-like behavior by promoting stress resilience","author":"Ji","year":"2019","journal-title":"Mol Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-38","first-page":"1284","article-title":"Schizophrenia, hypocretin (orexin), and the thalamocortical activating system","author":"Lambe","year":"2007","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/2394-8108.287734-39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/npp.2009.119","article-title":"Orexin\/hypocretin in psychiatric disorders: Present state of knowledge and future potential","author":"Borgland","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"key-10.4103\/2394-8108.287734-40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0306-4522(02)00017-9","article-title":"Anatomical substrates of orexin-dopamine interactions: Lateral hypothalamic projections to the ventral tegmental area","author":"Fadel","year":"2002","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.287734-41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.09.013","article-title":"Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: Systematic review and meta-analysis of randomized controlled trials","author":"Andrade","year":"2015","journal-title":"J Psychiatr Res"},{"key":"key-10.4103\/2394-8108.287734-42","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","article-title":"The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders","author":"Mereu","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/2394-8108.287734-43","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/j.1460-9568.2005.04121.x","article-title":"Dopaminergic regulation of orexin neurons","author":"Bubser","year":"2005","journal-title":"Eur J Neurosci"},{"key":"key-10.4103\/2394-8108.287734-44","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(00)02555-5","article-title":"Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system","author":"Nakamura","year":"2000","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-45","first-page":"1277","article-title":"The orexins\/hypocretins and schizophrenia","author":"Deutch","year":"2007","journal-title":"Schizophr Bull"},{"key":"key-10.4103\/2394-8108.287734-46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/sj.npp.1301239","article-title":"The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: Implications for antipsychotic therapy","author":"Rasmussen","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"key-10.4103\/2394-8108.287734-47","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ijnp\/pyy075","article-title":"Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics","author":"Chen","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"key-10.4103\/2394-8108.287734-48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/sj.mp.4001363","article-title":"Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects","author":"Dalal","year":"2003","journal-title":"Mol Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-49","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainres.2009.08.028","article-title":"Role of orexin\/hypocretin in dependence and addiction","author":"Sharf","year":"2010","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","author":"Marcus","year":"2001","journal-title":"J Comp Neurol"},{"key":"key-10.4103\/2394-8108.287734-51","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1471-4159.2007.04748.x","article-title":"Long-lasting up-regulation of orexin receptor type 2 protein levels in the rat nucleus accumbens after chronic cocaine administration","author":"Zhang","year":"2007","journal-title":"J Neurochem"},{"key":"key-10.4103\/2394-8108.287734-52","doi-asserted-by":"crossref","unstructured":"Carr D, Kalivas PW. Orexin: A gatekeeper of addiction. Nat Med 2006;12:274-6.","DOI":"10.1038\/nm0306-274"},{"key":"key-10.4103\/2394-8108.287734-53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.biopsych.2018.07.022","article-title":"Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats","author":"James","year":"2019","journal-title":"Biol Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-54","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/adb.12643","article-title":"Circulating orexin changes during withdrawal are associated with nicotine craving and risk for smoking relapse","author":"al'Absi","year":"2019","journal-title":"Addict Biol"},{"key":"key-10.4103\/2394-8108.287734-55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.psychres.2018.04.010","article-title":"Orexin A in men with heroin use disorder undergoing methadone maintenance treatment","author":"Tsai","year":"2018","journal-title":"Psychiatry Res"},{"key":"key-10.4103\/2394-8108.287734-56","first-page":"2866","article-title":"Orexin might predict status of alcohol dependence","author":"Pan","year":"2018","journal-title":"Chin Med J (Engl)"},{"key":"key-10.4103\/2394-8108.287734-57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","author":"Dauvilliers","year":"2007","journal-title":"Lancet"},{"key":"key-10.4103\/2394-8108.287734-58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/cap.2017.0085","article-title":"Atomoxetine, parent training, and their effects on sleep in youth with autism spectrum disorder and attention-deficit\/hyperactivity disorder","author":"Hollway","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"key-10.4103\/2394-8108.287734-59","first-page":"2514183x18794175","article-title":"Swiss narcolepsy scale: A simple screening tool for hypocretin-deficient narcolepsy with cataplexy","author":"Sturzenegger","year":"2018","journal-title":"Clin Transl Neurosci"},{"key":"key-10.4103\/2394-8108.287734-60","first-page":"48","article-title":"The effects of diurnal intermittent fasting on the wake-promoting neurotransmitter orexin-A","author":"Almeneessier","year":"2018","journal-title":"Ann Thorac Med","ISSN":"https:\/\/id.crossref.org\/issn\/1817-1737","issn-type":"print"},{"key":"key-10.4103\/2394-8108.287734-61","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1006\/bbrc.2001.6318","article-title":"Orexins activate histaminergic neurons via the orexin 2 receptor","author":"Yamanaka","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"key-10.4103\/2394-8108.287734-62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neurobiolaging.2017.01.011","article-title":"Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process","author":"Gabelle","year":"2017","journal-title":"Neurobiol Aging"},{"key":"key-10.4103\/2394-8108.287734-63","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson's disease","author":"Fronczek","year":"2007","journal-title":"Brain"},{"key":"key-10.4103\/2394-8108.287734-64","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","author":"Drouot","year":"2003","journal-title":"Neurology"},{"key":"key-10.4103\/2394-8108.287734-65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clineuro.2008.11.007","article-title":"Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease","author":"Asai","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"key-10.4103\/2394-8108.287734-66","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neulet.2014.07.014","article-title":"Neuroprotection by Orexin-A via HIF-1\u03b1 induction in a cellular model of Parkinson's disease","author":"Feng","year":"2014","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/2394-8108.287734-67","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fnins.2018.00835","article-title":"Orexin-A exerts neuroprotective effects via O\u00d71R in Parkinson's disease","author":"Liu","year":"2018","journal-title":"Front Neurosci"},{"key":"key-10.4103\/2394-8108.287734-68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuroscience.2017.11.008","article-title":"The subthalamic neurons are activated by both orexin-A and orexin-B","author":"Sheng","year":"2018","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.287734-69","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.neures.2010.08.005","article-title":"An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture","author":"Michinaga","year":"2010","journal-title":"Neurosci Res"},{"key":"key-10.4103\/2394-8108.287734-70","first-page":"185","article-title":"Heterogeneity and complexity in Alzheimer disease","author":"Hyman","year":"2019","journal-title":"Brain Pathol"},{"key":"key-10.4103\/2394-8108.287734-71","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.5665\/sleep.5846","article-title":"Orexin-A is associated with increases in cerebrospinal fluid phosphorylated-tau in cognitively normal elderly subjects","author":"Osorio","year":"2016","journal-title":"Sleep"},{"key":"key-10.4103\/2394-8108.287734-72","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.4103\/1673-5374.193224","article-title":"Impairment of the nerve growth factor pathway driving amyloid accumulation in cholinergic neurons: The incipit of the Alzheimer's disease story?","author":"Triaca","year":"2016","journal-title":"Neural Regen Res","ISSN":"https:\/\/id.crossref.org\/issn\/1673-5374","issn-type":"print"},{"key":"key-10.4103\/2394-8108.287734-73","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","article-title":"Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease","author":"Liguori","year":"2014","journal-title":"JAMA Neurol"},{"key":"key-10.4103\/2394-8108.287734-74","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/WNR.0b013e32833bfb7c","article-title":"Reduced hypocretin (orexin) levels in dementia with Lewy bodies","author":"Lessig","year":"2010","journal-title":"Neuroreport"},{"key":"key-10.4103\/2394-8108.287734-75","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3233\/JHD-190372","article-title":"the role of hypothalamic pathology for non-motor features of Huntington's disease","author":"Cheong","year":"2019","journal-title":"J Huntingtons Dis"},{"key":"key-10.4103\/2394-8108.287734-76","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1038\/s41598-018-27121-w","article-title":"Dual therapy with liraglutide and ghrelin promotes brain and peripheral energy metabolism in the R6\/2 mouse model of Huntington's disease","author":"Duarte","year":"2018","journal-title":"Sci Rep"},{"key":"key-10.4103\/2394-8108.287734-77","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/hmg\/ddi004","article-title":"Orexin loss in Huntington's disease","author":"Peters\u00e9n","year":"2005","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/2394-8108.287734-78","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","author":"Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"key-10.4103\/2394-8108.287734-79","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nlm.2018.11.008","article-title":"High fat diet increases cognitive decline and neuroinflammation in a model of orexin loss","author":"Duffy","year":"2019","journal-title":"Neurobiol Learn Mem"},{"key":"key-10.4103\/2394-8108.287734-80","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainres.2005.09.028","article-title":"Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease","author":"Meier","year":"2005","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s13311-019-00726-3","article-title":"Neurophysiological and behavioral effects of anti-orexinergic treatments in a mouse model of Huntington's disease","author":"Cabanas","year":"2019","journal-title":"Neurotherapeutics"},{"key":"key-10.4103\/2394-8108.287734-82","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2011.02.006","article-title":"Paradoxical function of orexin\/hypocretin circuits in a mouse model of Huntington's disease","author":"Williams","year":"2011","journal-title":"Neurobiol Dis"},{"key":"key-10.4103\/2394-8108.287734-83","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"key-10.4103\/2394-8108.287734-84","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2394-8108.287734-85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuroscience.2017.10.033","article-title":"Graph theoretical framework of brain networks in multiple sclerosis: A review of concepts","author":"Fleischer","year":"2019","journal-title":"Neuroscience"},{"key":"key-10.4103\/2394-8108.287734-86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neulet.2010.02.062","article-title":"CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients","author":"Papu\u0107","year":"2010","journal-title":"Neurosci Lett"},{"key":"key-10.4103\/2394-8108.287734-87","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.sleep.2007.11.022","article-title":"A patient with anti-aquaporin 4 antibody who presented with recurrent hypersomnia, reduced orexin (hypocretin) level, and symmetrical hypothalamic lesions","author":"Nozaki","year":"2009","journal-title":"Sleep Med"},{"key":"key-10.4103\/2394-8108.287734-88","first-page":"1039","article-title":"Orexin\/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis","author":"Pallais","year":"2020","journal-title":"Neural Regen Res","ISSN":"https:\/\/id.crossref.org\/issn\/1673-5374","issn-type":"print"},{"key":"key-10.4103\/2394-8108.287734-89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/bph.12277","article-title":"Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis","author":"Takata","year":"2013","journal-title":"Br J Pharmacol"},{"key":"key-10.4103\/2394-8108.287734-90","first-page":"487","article-title":"CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis","author":"Van","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"key-10.4103\/2394-8108.287734-91","first-page":"700","article-title":"Sleep disorders in amyotrophic lateral sclerosis: A questionnaire-based study from India","author":"Panda","year":"2018","journal-title":"Neurol India","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3886","issn-type":"print"},{"key":"key-10.4103\/2394-8108.287734-92","doi-asserted-by":"crossref","first-page":"e12782","DOI":"10.1111\/jsr.12782","article-title":"Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications","author":"Herring","year":"2019","journal-title":"J Sleep Res"},{"key":"key-10.4103\/2394-8108.287734-93","doi-asserted-by":"crossref","first-page":"145922","DOI":"10.1016\/j.brainres.2018.08.025","article-title":"Therapeutics development for addiction: Orexin-1 receptor antagonists","author":"Perrey","year":"2020","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-94","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: Results from two 3-month randomized controlled clinical Trials","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-95","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1113\/jphysiol.2013.256271","article-title":"Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats","author":"Li","year":"2013","journal-title":"J Physiol"},{"key":"key-10.4103\/2394-8108.287734-96","doi-asserted-by":"crossref","first-page":"e970","DOI":"10.4088\/JCP.16m11194","article-title":"Preventive effects of suvorexant on delirium: A randomized placebo-controlled trial","author":"Hatta","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"key-10.4103\/2394-8108.287734-97","first-page":"16","article-title":"Hypocretin (orexin) regulation of sleep-to-wake transitions","author":"De","year":"2014","journal-title":"Front Pharmacol"},{"key":"key-10.4103\/2394-8108.287734-98","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.09.024","article-title":"Addition of suvorexant to ramelteon therapy for improved sleep quality with reduced delirium risk in acute stroke patients","author":"Kawada","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key-10.4103\/2394-8108.287734-99","doi-asserted-by":"crossref","first-page":"145902","DOI":"10.1016\/j.brainres.2018.08.005","article-title":"A sleeping giant: Suvorexant for the treatment of alcohol use disorder?","author":"Campbell","year":"2020","journal-title":"Brain Res"},{"key":"key-10.4103\/2394-8108.287734-100","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/npp.2017.158","article-title":"Effects of suvorexant, a dual orexin\/hypocretin receptor antagonist, on impulsive behavior associated with cocaine","author":"Gentile","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"key-10.4103\/2394-8108.287734-101","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.euroneuro.2016.07.002","article-title":"Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects","author":"Struyk","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"key-10.4103\/2394-8108.287734-102","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","article-title":"On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30mg in healthy elderly","author":"Vermeeren","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"key-10.4103\/2394-8108.287734-103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.arr.2014.11.001","article-title":"Sleep disorders, obesity, and aging: The role of orexin","author":"Nixon","year":"2015","journal-title":"Ageing Res Rev"},{"key":"key-10.4103\/2394-8108.287734-104","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1073\/pnas.1521304113","article-title":"Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling","author":"Morello","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.4103\/2394-8108.287734-105","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1073\/pnas.1521304113","article-title":"Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling","author":"Morello","year":"2016","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:47:18Z","timestamp":1786733238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_42_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["287734"],"URL":"https:\/\/doi.org\/10.4103\/bc.bc_42_19","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}